ClinVar Miner

Submissions for variant NM_000419.5(ITGA2B):c.2029G>A (p.Glu677Lys)

dbSNP: rs2143450843
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Platelet Disorders Variant Curation Expert Panel, ClinGen RCV001580215 SCV001809848 likely pathogenic Glanzmann thrombasthenia 2024-06-06 reviewed by expert panel curation The NM_000419.5(ITGA2B):c.2029G>A (p.Glu677Lys) missense variant has a highest population minor allele frequency in gnomAD v4.0 of 0.000002625 (2/761904 alleles) in the European (non-Finnish)population, which is lower than the ClinGen PD VCEP threshold (<0.0001; PM2_Supporting). It has been reported in two patients with GT (PMID: 29675921, Patient 439 of the Glanzmann Thrombasthenia Database). GT1 of PMID: 29675921 is compound heterozygous for Glu677Lys and Arg351Ter (classified Pathogenic by the PD-EP SCV001809862.1; PM3_supporting). GT1 of PMID: 29675921 meets the criteria for PP4_strong; including mucocutaneous bleeding, impaired aggregation with all agonists except ristocetin, and <5% expression of αIIbβ3 measured by flow cytometry. ITGA2B and ITGB3 were sequenced across all exons and intron/exon boundaries. In summary, based on the evidence available at this time, the variant is classified as likely pathogenic. GT-specific criteria applied: PM2_supporting, PM3_supporting, and PP4_strong.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.